Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
Six months after launching with $60 million, Cambridge, Mass.-based Rheos Medicines has tapped Roche veteran Sanjay Keswani as the startup’s new chief executive officer.
Although there is a general complaint about drug prices, which rocketed into the public domain during the 2016 U.S. presidential election, nothing particularly dramatic has been done about it.
Each year, Peter Drucker’s Drucker Institute generates its Management Top 250, evaluating companies based on what it calls five dimensions of corporate performance. Those five dimensions are Customer Satisfaction, Employee Engagement and Development, Innovation, Social Responsibility and Financial Strength.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
Eli Lilly Oncology will have a new president at the helm of the division. Industry veteran Anne White has been tapped to lead the division beginning Sept. 1. She replaced Sue Mahoney whose last day with the company is today.
A spending bill passed in the U.S. Senate includes provisions taking aim at the high cost of prescription medicines by requiring pharmaceutical companies to disclose the cost of medications in television advertisements.
Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).
JOBS
IN THE PRESS